Publication details
Léčba chronických virových hepatitid v roce 2011
| Title in English | Treatment of chronic hepatitis in 2011 |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Medicína pro praxi |
| MU Faculty or unit | |
| Citation | |
| Field | Epidemiology, infectious diseases and clinical immunology |
| Keywords | viral hepatitis-pegylated interferon alpha-standard interferon alpha-adefovir dipivoxil-entecavir-telbivudine-tenofovir-ribavirin-boceprevir-telaprevir |
| Description | In 2011, there will be a major change in the treatmewnt of chronic hepatitis C virus (HCV) infection. The reason for this change is the commercial availability of novel antiviral drugs for the treatment of chronic HCV infection - telaprevir and boceprevir - in combination with pegylated interferon alfa and ribavirin. In naive patients as wel as in those in whom standard treatment dailed to eliminate HCV infection pernamently, the triple combination therapy is significantly more effective than the combination of PEG-IFN a ribavirin. |